Bio-Techne Corp (TECH)
71.88
-0.65
(-0.90%)
USD |
NASDAQ |
Mar 18, 16:00
71.88
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 11.30B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 0.13% |
Valuation | |
PE Ratio | 52.09 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 10.13 |
Price to Book Value | 5.754 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.08 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.2276 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 60.51% |
Profile
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%. |
URL | https://www.bio-techne.com |
Investor Relations URL | https://investors.bio-techne.com/ |
HQ State/Province | Minnesota |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Mid Cap/Blend |
Next Earnings Release | May. 03, 2024 (est.) |
Last Earnings Release | Feb. 01, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Feb. 09, 2024 |
Ratings
Profile
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%. |
URL | https://www.bio-techne.com |
Investor Relations URL | https://investors.bio-techne.com/ |
HQ State/Province | Minnesota |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Mid Cap/Blend |
Next Earnings Release | May. 03, 2024 (est.) |
Last Earnings Release | Feb. 01, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Feb. 09, 2024 |